Ibrutinib Capsules And Tablets

Q: Is PRODUCT_NAME available with DMF or regulatory documentation?

Yes, PRODUCT_NAME is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Q: Is PRODUCT_NAME exported internationally?

Yes, PRODUCT_NAME is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Form: Capsules and tablets

Strength: Capsule:140 mg, 70 mg; Tablet: 140 mg

Reference Brands: Imbruvica®(US & EU)

Category: Oncology Cancer Care

Ibrutinib (brand name Imbruvica®) is a BTK inhibitor used in oncology and hematology to treat B-cell malignancies like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. By blocking Bruton’s tyrosine kinase (BTK), Ibrutinib disrupts B-cell signaling, preventing cancerous B-cell growth. Available in oral capsules (70 mg, 140 mg) and oral tablets (140 mg), it is approved for use in both the US and EU. Marketed by AbbVie and Janssen Pharmaceuticals, Imbruvica® is a key product for B2B pharmaceutical transactions in the oncology and hematology sectors.

Get Enquiry 📘 Sourcing Guide Document

Quick Response Guaranteed | Verified Suppliers

Back to Listing

Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Frequently Asked Questions

Yes, Ibrutinib Capsules and tablets is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Ibrutinib Capsules and tablets is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Ibrutinib Capsules And Tablets

Frequently Asked Questions

Related Products

Vimseltinib

Atezolizumab

Durvalumab

Sunitinib

Ibrutinib Capsules And Tablets

Frequently Asked Questions

Is Ibrutinib Capsules and tablets available with DMF or regulatory documentation?

Can I request a sample of Ibrutinib Capsules and tablets before placing a bulk order?

What certifications does the manufacturer of Ibrutinib Capsules and tablets hold?

What is the typical lead time for bulk orders of Ibrutinib Capsules and tablets?

Is Ibrutinib Capsules and tablets exported internationally?

Related Products

Vimseltinib

Atezolizumab

Durvalumab

Sunitinib

Subscribe to Our Newsletter